<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716651</url>
  </required_header>
  <id_info>
    <org_study_id>RBB1</org_study_id>
    <secondary_id>EudraCT 2006-001791-20</secondary_id>
    <nct_id>NCT00716651</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome</brief_title>
  <acronym>MEPOCHUSS</acronym>
  <official_title>A Phase II, Single Center Open Label, Prospective Trial to Evaluate the Efficacy and Safety of Mepolizumab for Patients With Refractory or Relapsing Churg Strauss Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Churg-Strauss syndrome is a rare type of systemic vasculitis which occurs almost exclusively&#xD;
      in patients with asthma and which is characterized by prominent blood and tissue&#xD;
      eosinophilia. The disease has a chronic smoldering course with a permanent need for medium to&#xD;
      high corticosteroid doses. Available unselective immunosuppressive agents are often&#xD;
      insufficient to reduce corticosteroid doses, to induce complete remission and to protect&#xD;
      patients from disease flares which occur in more than 50 % of cases.&#xD;
&#xD;
      Interleukin-5 is the most potent cytokine regulating the production of eosinophil&#xD;
      granulocytes which are the major effector cells in Churg-Strauss syndrome. Recently, an&#xD;
      increased production of interleukin-5 was demonstrated in Churg-Strauss syndrome. Mepolizumab&#xD;
      is a monoclonal IgG antibody targeting interleukin-5 and is effective in the treatment of the&#xD;
      HES. The hypothesis of this study is, that mepolizumab will induce remission and allow for&#xD;
      steroid reduction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint is the percentage of patients with Churg-Strauss Syndrome that attain remission</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BVAS score</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Extent Index score</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent End organ damage assessed by the Vasculitis Damage Index</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to remission</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response, defined as a 50 % reduction of the BVAS score</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of relapses</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood eosinophil count</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of all AEs and SAEs</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Churg Strauss Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mepolizumab</intervention_name>
    <description>750 mg mepolizumab iv q4wk until week 32</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  documented history of Churg Strauss Syndrome&#xD;
&#xD;
          -  active disease&#xD;
&#xD;
          -  subjects must complete screening and baseline assessment&#xD;
&#xD;
          -  stable corticosteroid dose of &gt; 12.5 mg prednisolone for at least one week&#xD;
&#xD;
          -  treatment with cyclophosphamide (pulse or daily oral) or methotrexate or azathioprin&#xD;
             or leflunomide in a stable dose for at least 4 weeks&#xD;
&#xD;
          -  not pregnant or nursing&#xD;
&#xD;
          -  negative pregnancy test and agree to practice birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  life threatening disease or other critical illness deemed inappropriate for inclusion&#xD;
             in the study by the principal investigator&#xD;
&#xD;
          -  treatment with other immunosuppressive agents within 4 weeks prior to randomisation&#xD;
&#xD;
          -  corticosteroid pulse of &gt; 60 mg within the last three weeks prior to randomisation&#xD;
&#xD;
          -  known secondary cause of eosinophilia&#xD;
&#xD;
          -  no history or clinical features of vasculitis&#xD;
&#xD;
          -  diagnosis of other primary systemic vasculitis&#xD;
&#xD;
          -  currently active malignant disease&#xD;
&#xD;
          -  abnormal laboratory values&#xD;
&#xD;
          -  impaired cardiac function&#xD;
&#xD;
          -  history of allergic reaction due to monoclonal antibodies&#xD;
&#xD;
          -  prior treatment with anti-hIL-5 monoclonal antibody&#xD;
&#xD;
          -  exposure to investigational drug within 30 days prior to randomisation&#xD;
&#xD;
          -  positive pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Schleswig Holstein, Rheumaklinik Bad Bramstetd</name>
      <address>
        <city>Bad Bramstedt</city>
        <state>SH</state>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Moosig</investigator_full_name>
    <investigator_title>PD Dr. Frank Moosig</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

